{"schema_version":"secwatch.filing_event.v1","accession":"0001872789-22-000019","form_type":"8-K","ticker":"EMBC","cik":"0001872789","company_name":"Embecta Corp.","filed_at":"2022-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.871481+00:00","generated_at":"2026-06-21T02:02:51.586563+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Embecta reports Q4 FY2022 net loss $17.2M; FY2023 guidance revenue $1,050-$1,073M","bullets":["Q4 revenue $274.6M, down 8.7% reported; net loss $17.2M vs income $97.1M prior year, includes $58.9M impairment.","FY2022 revenue $1,129.5M, down 3.1%; net income $223.6M vs $414.8M; adjusted EBITDA margin 40.7% vs 48.5%.","Quarterly dividend $0.15/share declared, payable Jan 11, 2023 to holders of record Dec 30, 2022.","Preliminary FY2023 guidance: revenue $1,050-$1,073M (down 5-7% reported); adj. diluted EPS $1.75-$2.00.","Entered co-promotion agreement with Intuity Medical for POGO Automatic blood glucose monitor in U.S."],"urls":{"canonical":"https://secwatch.observer/filing/0001872789-22-000019","json":"https://secwatch.observer/filing/0001872789-22-000019.json","markdown":"https://secwatch.observer/filing/0001872789-22-000019.md","text":"https://secwatch.observer/filing/0001872789-22-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1872789/000187278922000019/0001872789-22-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1872789/000187278922000019/embc-20221220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T02:02:51.586563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02ef1ad1580ebd40521760bbb45e59b6f6b76f61","claim":"Embecta Corp. reported the twelve months ended September 30, 2022 results: revenue $1,129.5 million, net income $223.6 million.","evidence_excerpt":"Twelve Months Ended September 30 Fiscal Year 2022 Financial Highlights : • Revenues of $1,129.5 million, down 3.1% on a reported basis; down 0.5% on a constant currency basis","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1872789/000187278922000019/0001872789-22-000019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the twelve months ended September 30, 2022"},{"label":"Revenue","value":"$1,129.5 million"},{"label":"Net income","value":"$223.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"fd5f216dcaa77ab226329c01ca752669df9f8ff0","claim":"Embecta Corp. reported the three months ended September 30, 2022 results: revenue $274.6 million, net income $(17.2) million.","evidence_excerpt":"Fourth Quarter Fiscal Year 2022 Financial Highlights : • Revenues of $274.6 million, down 8.7% on a reported basis; down 4.2% on a constant currency basis","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1872789/000187278922000019/0001872789-22-000019-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Revenue","value":"$274.6 million"},{"label":"Net income","value":"$(17.2) million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}